Bristol Myers Squibb (BMS) is a leading pharmaceutical company headquartered in New York City, United States. It was founded in 1887 as Bristol-Myers, and later merged with Squibb Corporation in 1989 to form Bristol Myers Squibb. BMS primarily focuses on developing and manufacturing innovative medicines to improve patient outcomes across various therapeutic areas.

The company's main products include prescription medications for cardiovascular diseases, oncology, immunology, neuroscience, and virology. Noteworthy products from BMS include the anticoagulant Eliquis, the cancer drug Opdivo, and the immunosuppressant Orencia. On a global scale, Bristol Myers Squibb has a strong presence and operates in numerous countries.

The company has established subsidiaries and joint ventures in various regions, partnering with local companies to expand its reach. Notable subsidiaries include Celgene Corporation, acquired by BMS in 2019, which specializes in cancer treatments. BMS has also formed partnerships with other pharmaceutical companies, academic institutions, and research organizations to collaborate on drug development and research projects.

In terms of market position, BMS is considered one of the top pharmaceutical companies globally. It generates significant revenue through its diverse product portfolio and maintains a strong presence in global markets. With a focus on innovation and research, BMS continually strives to develop breakthrough therapies and maintain its leading position in the industry.

Over the years, Bristol Myers Squibb has experienced several major events and achievements. In 2019, BMS completed its acquisition of Celgene Corporation, expanding its oncology portfolio and pipeline. This acquisition positioned BMS as a leader in the oncology space.

Additionally, the company has made strategic changes to its product lineup, focusing on high-potential therapeutic areas to drive growth and meet patient needs. Currently, Bristol Myers Squibb continues to be a prominent player in the pharmaceutical industry. The company regularly announces updates on its pipeline, partnerships, and regulatory milestones.

As of the latest information available, BMS remains committed to expanding its global presence, driving innovation, and bringing new therapies to patients worldwide